Monitor for partnership announcements and EVX-01 three-year data in H2 2026. Current cash runway into H2 2027 suggests no near-term financing urgency, but the widened net loss and pre-revenue status imply eventual capital needs.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $4.07entry
- T+1 · 6mo ago +6.63%α +5.80% · $4.34
- T+5 · 6mo ago +2.21%α +0.71% · $4.16
- T+20 · 6mo ago −13.02%α −16.16% · $3.54
- T+60 · 4mo ago −31.45%α −35.28% · $2.79
Price Chart
How similar events traded
Executive Summary
Evaxion reported Q1 2026 results with net loss widening to $3.6M from $1.6M due to lower financial income, while operating expenses remained roughly flat. Cash of $18.4M provides runway into H2 2027. R&D progress includes positive immunogenicity data for EVX-01 (86% target recognition) and completion of phase 2 extension, but no new partnerships or near-term catalysts were announced.
Key Facts
- Net loss Q1 2026: $3.6M vs $1.6M Q1 2025 (increase due to lower financial income)
- Operating loss slightly improved: -$3.819M vs -$3.868M
- Cash and equivalents: $18.4M as of March 31, 2026 (down from $23.2M at Dec 31, 2025)
- Cash runway confirmed into second half of 2027
- No revenue; zero revenue in both periods
- 86% vaccine target recognition rate reported for EVX-01 from AACR data
- Phase 2 extension for EVX-01 completed; three-year data expected H2 2026
- New polio vaccine design concepts presented from Gates Foundation collaboration
- Promoted Chief Scientific/COO and added new Board member with dealmaking experience
Financial Impact
Net loss increased $2.0M YoY due to $2.2M decline in financial income; cash burn ~$3.6M/quarter
Risk Factors
- No near-term revenue and increasing net loss
- Need for additional capital beyond current runway
- Clinical trial risks for EVX-01 and pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003114 |
| Document: f6k_050726.htm | 0001171843-26-003114 |
| Document: 0001171843-26-003114-index-headers.html | 0001171843-26-003114 |
| Document: 0001171843-26-003114-index.html | 0001171843-26-003114 |
| Document: 0001171843-26-003114.txt | 0001171843-26-003114 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers